Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial – The Lancet HIV

Invited Commentary: Game-changing study of second-line HIV treatment – The Lancet HIV (free registration required)

Original Study: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine

Commentary on Twitter

Efficacy and safety of DTG or DRV in combination with 3TC + ZDV or TDF for second-line treatment of HIV infection (NADIA)… https://t.co/XajA2rLzsp DTG & DRV-based ART maintain good viral suppression during 96 wks; DTG non-inferior to DRV but ⬆️risk of resistance in 2rd-line Rx.

— Carlos del Rio (@CarlosdelRio7) April 21, 2022